PMID- 30535428
OWN - NLM
STAT- MEDLINE
DCOM- 20190528
LR  - 20211204
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 19
IP  - 2
DP  - 2019 Feb
TI  - Gambogic acid prevents angiotensin II‑induced abdominal aortic aneurysm through 
      inflammatory and oxidative stress dependent targeting the PI3K/Akt/mTOR and NF‑kappaB 
      signaling pathways.
PG  - 1396-1402
LID - 10.3892/mmr.2018.9720 [doi]
AB  - Gamboge is the dry resin secreted by Garcinia hanbaryi Hook.f, with the function 
      of promoting blood circulation and anti‑cancer effects, detoxification, 
      hemostasis and killing insects. It is also used for the treatment of cancer, 
      brain edema and other diseases. Gambogic acid is the main effective constituent 
      of Gamboge. The present study tested the hypothesis that the effect of Gambogic 
      acid prevents angiotensin II‑induced abdominal aortic aneurysm (AAA), and 
      explored its underlying mechanism. It was demonstrated that gambogic acid 
      significantly inhibited AAA incidence rate, and reduced edge leading aortic 
      diameter and aortic wall thickness in AAA mice. Gambogic acid treatment markedly 
      decreased the levels of proinflammatory cytokines and oxidative stress factors, 
      and transforming growth factor‑beta (TGF‑beta) and matrix metalloproteinase (MMP)‑2 and 
      MMP‑9 protein expression in AAA mice. Furthermore, Gambogic acid decreased 
      expression of phosphatidylinositol 3‑kinase (PI3K), and phosphorylation of 
      protein kinase B (Akt), mechanistic target of rapamycin (mTOR) and p70‑S6 kinase 
      1. It also suppressed nuclear factor (NF)‑kappaB protein expression in AAA mice. The 
      findings of the present study indicated that Gambogic acid prevents angiotensin 
      II‑induced AAA through inflammatory and oxidative stress‑dependent targeting of 
      the PI3K/Akt/mTOR and NF‑kappaB signaling pathways.
FAU - Liu, Qiang
AU  - Liu Q
AD  - Department of Vascular Surgery, The First Hospital of Qiqihar City, Qiqihar, 
      Heilongjiang 161021, P.R. China.
FAU - Shan, Peng
AU  - Shan P
AD  - Department of Vascular Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, Heilongjiang 150036, P.R. China.
FAU - Li, Haibin
AU  - Li H
AD  - Department of Vascular Surgery, The First Hospital of Qiqihar City, Qiqihar, 
      Heilongjiang 161021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181204
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (NF-kappa B)
RN  - 0 (Xanthones)
RN  - 11128-99-7 (Angiotensin II)
RN  - 8N585K83U2 (gambogic acid)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Aortic Aneurysm, Abdominal/*chemically induced/metabolism/*prevention & control
MH  - Garcinia/metabolism
MH  - Inflammation/*metabolism
MH  - Male
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/metabolism
MH  - Oxidative Stress/*drug effects
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Xanthones/*pharmacology
OTO - NOTNLM
OT  - gambogic acid
OT  - abdominal aortic aneurysm
OT  - phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin
OT  - nuclear factor-kappaB
EDAT- 2018/12/12 06:00
MHDA- 2019/05/29 06:00
CRDT- 2018/12/12 06:00
PHST- 2016/10/08 00:00 [received]
PHST- 2017/09/12 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/05/29 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
AID - 10.3892/mmr.2018.9720 [doi]
PST - ppublish
SO  - Mol Med Rep. 2019 Feb;19(2):1396-1402. doi: 10.3892/mmr.2018.9720. Epub 2018 Dec 
      4.